New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 24, 2012
08:20 EDTRPTPRaptor Pharma weakness may provide buying opportunity, says Oppenheimer
After Raptor announced that the FDA had postponed its decision on approving Raptor's Procysbi for three months until April 30, 2013, Oppneheimer views the news as a short-term negative for the company but doesn't think it has any implication on the FDA's ultimate decision about Procysbi. The firm maintains an Outperform rating on Raptor.
News For RPTP From The Last 14 Days
Check below for free stories on RPTP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 11, 2014
15:46 EDTRPTPHealthCare Royalty Partners reports 5.2% passive stake in Raptor Pharmaceuticals

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use